Many human hereditary neurodegenerative diseases are caused by expanded CAG repeats, and anonymous CAG expansions have also been described in schizophrenia and bipolar disorder. We have isolated and sequenced a novel human cDNA encoding a neuronal, small conductance calcium-activated potassium channel (hSKCa3) that contains two arrays of CAG trinucleotide repeats. The second CAG repeat in hSKCa3 is highly polymorphic in control individuals, with alleles ranging in size from 12 to 28 repeats. The overall allele frequency distribution is significantly different in patients with schizophrenia compared to ethnically matched controls (Wilcoxon Rank Sum test, P = 0.024), with CAG repeats longer than the modal value being over-represented in patients (Fisher Exact test, P = 0.0035). A similar, non-significant, trend is seen for patients with bipolar disorder. These results provide evidence for a possible association between longer alleles in the hSKCa3 gene and both of these neuropsychiatric diseases, and emphasize the need for more extensive studies of this new gene. Small conductance calcium-activated K + channels play a critical role in determining the firing pattern of neurons. These polyglutamine repeats may modulate hSKCa3 channel function and neuronal excitability, and thereby increase disease risk when combined with other genetic and environmental effects.
Many human hereditary neurodegenerative diseases are caused by expanded CAG repeats, and anonymous CAG expansions have also been described in schizophrenia and bipolar disorder. We have isolated and sequenced a novel human cDNA encoding a neuronal, small conductance calcium-activated potassium channel (hSKCa3) that contains two arrays of CAG trinucleotide repeats. The second CAG repeat in hSKCa3 is highly polymorphic in control individuals, with alleles ranging in size from 12 to 28 repeats. The overall allele frequency distribution is significantly different in patients with schizophrenia compared to ethnically matched controls (Wilcoxon Rank Sum test, P = 0.024), with CAG repeats longer than the modal value being over-represented in patients (Fisher Exact test, P = 0.0035). A similar, non-significant, trend is seen for patients with bipolar disorder. These results provide evidence for a possible association between longer alleles in the hSKCa3 gene and both of these neuropsychiatric diseases, and emphasize the need for more extensive studies of this new gene. Small conductance calcium-activated K + channels play a critical role in determining the firing pattern of neurons. These polyglutamine repeats may modulate hSKCa3 channel function and neuronal excitability, and thereby increase disease risk when combined with other genetic and environmental effects.
Several human hereditary neurodegenerative diseases (Huntington's disease, fragile X syndrome, myotonic dystrophy, spinal and bulbar muscular atrophy, Machado-Joseph disease, Friedreich's ataxia and spinocerebellar ataxia) are Mendelian traits, generally dominant, caused by expanded trinucleotide repeats within the coding regions, untranslated sequences, or introns of genes. [1] [2] [3] [4] A subset of these mutations caused by expansion of CAG trinucleotide repeats encodes polyglutamine arrays that are typically longer than 35 repeats, suggesting that alterations in protein structure and function contribute to the development of these diseases. However, since the function of most of these proteins is unknown, the molecular mechanisms of pathogenesis remain elusive. Recently, mild CAG expansions within the ␣1-calcium channel gene (21-27 repeats, with 4-17 repeats in normal alleles) were described in a subset of patients with spinocerebellar ataxia (SCA), patients having the expansion (found in eight of 266 patient-chromosomes) being given the diagnosis of SCA-6; 5 replicative studies now show normal alleles with up to 20 repeats, producing a continuous distribution of normal and pathogenic allele lengths. [6] [7] [8] This protein has a well-defined function within neurons, and, although this has yet to be tested, electrophysiological strategies should easily discern even subtle changes in channel function resulting from polyglutamine repeats longer by even one glutamine.
Recently, longer anonymous CAG arrays have been reported in patients with schizophrenia and bipolar disorder-I (BPD-I), diseases lacking obvious neurodegeneration, with considerable overlap in the repeat lengths between patient and control populations. [9] [10] [11] [12] Such overlap is expected for common, heterogeneous, genetically complex, non-Mendelian disorders like schizophrenia and BPD-I that also have a significant environmental component. One would no longer expect to find CAG expansion alleles of a given locus uniquely associated with disease. In fact, one would expect control populations to always contain some longer susceptibility alleles, and only a subset of patients to carry such alleles. [9] [10] [11] [12] Despite extensive studies, the precise gene(s) containing the longer CAG alleles associated with neuropsychiatric disorders remain unidentified. [13] [14] [15] In this study, we describe a novel potassium channel gene, hSKCa3, involved in neuronal excitability, that shows the predicted signifi- ) is derived from a combination of the published AAD14 cDNA, our human genomic and brain cDNA sequences, and the human EST AA285078; rSKCa3 is derived from the published cDNA sequence. The putative transmembrane segments and pore region are bracketed, and the two polyglutamine arrays are shown in bold and bracketed. (b) Alignment of nucleotide sequences of hSKCa3 and the human STS G16005. The hSKCa3 sequence begins just before the start of the coding region (the initiating 'AUG' is shown in bold) and continues through the sequence encoding the residue at position 225, within the putative N-terminal cytoplasmic region of the protein. The two 'CAG' trinucleotide repeats are bracketed, and an allelic difference is evident in the length of the second repeat.
cant excess of longer CAG-repeat alleles in psychiatric patients compared with ethnically matched controls.
The hSKCa3 gene encodes a protein of 731 amino acids containing two polyglutamine arrays in its N-terminus ( Figure 1a ). We initially identified partial hSKCa3 sequences 16 in the database (accession Nos Y08263, AA285078) using query sequences from the newly discovered family of small conductance calcium-activated K + (SKCa) channel genes. 17 Using PCR primers based on these sequences, we cloned and determined the full length hSKCa3 coding sequence. The human genomic sequence, STS-G16005, aligns with the hSKCa3 cDNA sequence from nt 328-955 in a region that includes the two CAG arrays (Figure 1b) . The STS corresponds to CHLC marker GCT10H06 (found in CHLC under 'GCT10').
Both polyglutamine repeats exhibit polymorphism in their length. The first repeat contains 12 residues in 24 sequenced samples, but contains 10 residues in one other sample. The second polyglutamine repeat is highly polymorphic, with seven distinct alleles among 13 sequenced control samples, ranging from 13 to 19 repeats. Using a microsatellite assay, we genotyped the second repeat in 319 chromosomes in unrelated Caucasian adult controls from Europe and USA. 13, 18 Alleles ranged in length from 12 to 28 CAG repeats, the modal length being 19 repeats for both populations ( Figure  2 ). We also sampled 44 unselected Caucasian neonates whose allele distribution and modal repeat length (19 repeats) was indistinguishable from adult controls (data not shown).
Is hSKCa3 a reasonable candidate gene? First, SKCa channels are known to play a vital role in determining the firing pattern of neurons via the generation of slow afterhyperpolarizations and the regulation of intracellular calcium signals. 19 Alterations in hSKCa3 channel function might be expected to affect neural excitability. An example of this behavior is relevant to the psychiatric diseases. While toxic and therapeutic drug responses have both implicated NMDA-receptor hypofunction in these diseases, linkage studies have eliminated many glutamate-receptor and dopamine receptor genes as plausible disease candidates. [20] [21] [22] [23] [24] [25] [26] SKCa channels hyperpolarize the membrane potential, 21 and thereby inactivate NMDA-receptors. Hyperactive hSKCa3 channels would therefore be expected to induce NMDA receptor hypo-function and might thereby enhance disease susceptibility. Second, rSKCa3 (the rat homologue), and therefore most likely hSKCa3, is expressed in many relevant regions of the brain. 17 Third, the hSKCa3 protein contains a polymorphic polyglutamine stretch in its N-terminus (Figure 1 ) which could be altered in disease; longer anonymous CAG arrays have been previously reported in patients with schizophrenia and BPD-I. [9] [10] [11] [12] Additionally, intergenerational lengthening of the hSKCa3 CAG repeat may contribute to the phenomenon of 'anticipation' (increase in severity and decrease in age of onset in successive generations) that has been described for these disorders. 27 In order to help clarify the complex genetic basis of these neuropsychiatric diseases, we have embarked on case-control studies as a first test of the candidate role for hSKCa3. We have used two Caucasian populations which have previously been used in published studies. 13, 18 These cohorts were analyzed independently in Europe and in the USA, to determine if the presence of longer CAG repeats in hSKCa3 is associated with neuropsychiatric disorders. Caucasian patients with schizophrenia were compared with ethnically matched, unrelated, screened adult controls. A similar comparison was carried out for patients with BPD-I. Figure 2 shows the frequency of alleles with different CAG repeat lengths for schizophrenia patients and controls. Using the Wilcoxon Rank-Sum test with tied midranks and collapsed tails, 28 we find that the distributions of allele frequencies are significantly different between European schizophrenia patients and controls (P = 0.023), with an excess of longer alleles in patients (Figure 2a) . This difference remains significant after pooling the European and the smaller number of USA samples (P = 0.024), shown in Figure 2b . Analyses of these data after dichotomizing the samples at the modal allele length (19 repeats for all groups) yield similar results. Use of the Fisher Exact test shows a significant excess of alleles longer than the modal value in the European schizophrenia patients compared with adult controls (P = 0.0078); this remains significant after the European and USA samples are pooled (P = 0.0035). Using the same dichotomization, a similar trend (although not statistically significant) towards an excess of longer alleles was observed among the smaller number of cases with BPD-I in both the European and USA samples (data not shown).
These results are remarkably similar to earlier reports showing longer anonymous CAG repeats in patients with these diseases, but with considerable overlap between patient and control populations. Such an overlap is expected for common, heterogeneous and polygenic diseases like schizophrenia and BPD-I that affect between 0.5-1.5% of the human population, and are major contributors to morbidity and mortality worldwide. This would be especially true for a candidate gene for such polygenic disorders, since any one locus may contribute only a small portion of overall disease susceptibility and may be neither sufficient nor necessary for disease development. [29] [30] [31] [32] [33] [34] [35] Not all patients will express susceptibility alleles at this locus, and controls may well express such alleles. Furthermore, if a single longer allele is sufficient to increase disease risk, half the patient alleles will in fact be 'normals'.
Since this channel is expressed in many relevant regions of the brain 17 and is known to regulate neuronal activity, 19 it is easy to envision a pathogenic mechanism involving subtle alterations in channel function (and therefore neuronal behavior) produced by mild variations in the length of the polyglutamine repeats. This mechanism is reminiscent of the continuous distribution of alleles for the ␣1-calcium channel gene involved in SCA-6.
5-8 If a change in length by a single glutamine in an array can result in a perceptible change in channel function, one might expect a continuous gradation of effects of polyglutamine length on the channel's biophysical properties. The resulting consequences for neuronal excitability, and therefore disease susceptibility, will depend on the interplay between the complex ensemble of channel types and many other cellular regulators. These hypothesized ion channel alterations, although subtle, can readily be resolved, even at the level of single molecules, by wellestablished techniques for electrophysiological analysis. It is also worth noting that there are well-recognized interactions between the activity of voltage-gated calcium channels, like that encoded by the ␣1-calcium channel gene, calcium-activated potassium channels such as that encoded by hSKCa3, and NMDAreceptors. Since each channel type has the potential to control the activity of the other, alterations of function in any of these important proteins might perturb a common physiological process.
In conclusion, we describe a novel neuronal potassium channel gene, hSKCa3, which contains a highly polymorphic CAG repeat, and for which longer alleles are over-represented in patients with neuropsychiatric disorders. These encouraging results highlight the need for a more thorough evaluation of the potential contribution of hSKCa3 to psychiatric disease susceptibility with studies of larger and more ethnically diverse cohorts. In addition, detailed electrophysiological analyses of hSKCa3 may elucidate the relationship between channel function, polyglutamine-repeat length and disease susceptibility, as well as clarifying the more general role of glutamine repeats in modifying protein structure and function.
Methods

Clinical description
All studies were performed after approval by the local ethics committees and with the informed consent of all subjects. All patients and controls described here have previously been used in other published studies. 13, 18 European patients: Unrelated patients of French or Alsatian ancestry meeting DSM-IV criteria for schizophrenia or BPD-I were genotyped; Mediterranean Caucasians, Asians, and Africans were excluded. Patients were examined with an unstructured clinical interview and also with a structured clinical interview (SADSLifetime Version, 35 final diagnoses being made by a consensus of two psychiatrists.
European controls: Controls were recruited from among the healthy staff and students at the same hospital as the patients. They were older than 25 years and had no history of psychiatric disease. They are ethnically matched to the patients and live in the same geographical area.
USA patients: The cohort included inpatients and outpatients at the Schizophrenia module of the Western Psychiatric Institute and Clinic (WPIC). Caucasian patients with a diagnosis of schizophrenia or BPD-I by DSM-IV criteria, determined by a semi-structured interview, were recruited into the study.
USA controls: The controls were matched for ethnicity and resided in the same geographical area as the patients. These individuals were screened for a lifetime history of substance abuse, autoimmune disease, psychosis or major depressive disorder (Research Diagnostic Criteria: RDC).
USA neonatal controls: The second group of controls consisted of neonates born during 1993-94 at MageeWomen's Hospital (MWH) in Pittsburgh. Umbilical cord blood samples (10 ml) were obtained from live births of Caucasian ethnicity.
Microsatellite assay USA study: The following PCR primers flanking both repeats were used to amplify an approximately 470-bp fragment from control and patient genomic DNAs:
for:-5Ј-ACCCCAAGTGCCCCTGTCCATCC-3Ј rev:-5Ј-ATCTCCGTGAAGGGGTTGCTGTCC-3Ј These coded samples were then shipped for blinded analysis using nested primers flanking the second polymorphic repeat:
for:-5Ј-CACCGTCAGTGTCACCAGTAGTCCCC-3Ј rev:-5Ј-GAAGGGGTTGCTGTCCCGCCGGT-3Ј
These primers amplified ෂ380-bp internal fragments from the initial PCR products; the reverse primer was fluoresceinated at the 5Ј-end. The PCR products were diluted in formamide loading buffer, denatured at 95°C for 10 min and loaded onto a denaturing sequencing gel with molecular weight markers (No. 27-4525-01, Pharmacia Biotech, Uppsala, Sweden). Three cloned sequenced alleles of known repeat length were run on each gel as internal controls and for the purpose of calibration. The sizes of the fluoresceinated PCR products were determined with the Pharmacia ALF DNA sequencer in the Biotechnology Resource Facility at the University of California, Irvine. PCR conditions: 40 cycles of 94°C/30ЈЈ, 65°C/30ЈЈ, 72°C/45ЈЈ after initial denaturation at 94°C for 3 min.
European study: PCR primers flanking both repeats were used to generate an approximately 357-bp fragment:
for:-5Ј-AAGTGCCCCTGTCCATCCTCT-3Ј rev:-5Ј-GCCAAGCAAGTGGTCATTGAG-3Ј
The forward primer was 5Ј end-labeled with gamma 32 P-ATP using T4 polynucleotide kinase. PCR conditions were: 30 cycles of 96°C/45ЈЈ, 59°C/45ЈЈ, 72°C/45ЈЈ, after initial denaturation at 95°C for 5Ј and final extension at 72°C for 7Ј. PCR products were analyzed on 6% denaturing PAGE followed by autoradiography. pUC18 sequence was used for allele sizing.
Comparison between the two studies. European and USA samples were calibrated using the same 2-3 sequenced clones of known repeat lengths. Five patient samples were independently genotyped by the European and USA groups. The number of CAG repeats estimated by both groups was identical for four samples, and differed by one repeat for one of two alleles in the fifth sample.
